Emory University

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Regeneron Bolsters Ophthalmic Portfoli

The goal of gene therapy for severe hemophilia A patients is to decrease the annual bleed rate (ABR) and reduce the treatment burden of frequent prophylactic Factor VIII infusions, but hematologists a

Amgen, Inc. ’s Imdelltra (tarlatamab) for extensive-stage small cell lung cancer (ES-SCLC) is one of only two bispecific T-cell engagers (BiTEs) approved in the US to treat solid tumors. As additional

Twelve biopharmaceutical companies announced venture capital financings totaling $672m between 7 and 11 February, which was another relatively quiet week for public company offerings. With biotechnolo